



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Øystein Evensen
✉ oystein.evensen@nmbu.no

RECEIVED 22 September 2024
ACCEPTED 23 September 2024
PUBLISHED 02 October 2024

CITATION
Xu C, Gamil AAA, Wang X, Munang'andu HM
and Evensen Ø (2024) Corrigendum: MAVS
disruption impairs downstream signaling and
results in higher virus replication levels of
salmonid alphavirus subtype 3 but not
infectious pancreatic necrosis virus *in vitro*.
Front. Immunol. 15:1500204.
doi: 10.3389/fimmu.2024.1500204

COPYRIGHT
© 2024 Xu, Gamil, Wang, Munang'andu and
Evensen. This is an open-access article
distributed under the terms of the [Creative
Commons Attribution License \(CC BY\)](#). The
use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in
this journal is cited, in accordance with
accepted academic practice. No use,
distribution or reproduction is permitted
which does not comply with these terms.

Corrigendum: MAVS disruption impairs downstream signaling and results in higher virus replication levels of salmonid alphavirus subtype 3 but not infectious pancreatic necrosis virus *in vitro*

Cheng Xu¹, Amr A. A. Gamil¹, Xiaolin Wang²,
Hetron Mweemba Munang'andu³ and Øystein Evensen^{1*}

¹Department of Paraclinical Sciences, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Ås, Norway, ²Fishteck AS, Oslo, Norway, ³Faculty of Biosciences and Aquaculture, Nord University, Bodø, Norway

KEYWORDS

MAVS, Sensing, salmonid alphavirus, infectious pancreatic necrosis virus, disruption, TALEN

A Corrigendum on

MAVS disruption impairs downstream signaling and results in higher virus replication levels of salmonid alphavirus subtype 3 but not infectious pancreatic necrosis virus *in vitro*

By Xu C, Gamil AAA, Wang X, Munang'andu HM and Evensen Ø (2024). *Front. Immunol.* 15:1401086. doi: 10.3389/fimmu.2024.1401086

In the published article, there was an error in affiliation 2. Instead of “Next Generation Sequencing (NGS) Oncology for Nordic & Baltic Region, Thermo Fisher Scientific, Oslo, Norway”, it should be “Fishteck AS, Oslo, Norway”.

In the published article, the **Conflict of Interest** section has been updated to include the new commercial affiliation for author XW. The correct **Conflict of Interest** statement appears below.

“Author XW was employed by company Fishteck AS.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.